|
Targeting
tropical diseases
In a bid to fill their depleting research pipelines, multinational
pharmacos are targeting neglected segments like tropical diseases.
This is good news for developing markets like India which
represent a table full of opportunities. Sushmi Dey finds
out more
NPIL
is now Piramal Healthcare
After 20 years of operations, Nicholas Piramal India Limited
(NPIL) is acquiring a new corporate identity—Piramal
Healthcare.
Sun
gets US FDA nod
Sun Pharma announced that US FDA has granted final approval
for the company's abbreviated new drug application (ANDA)
to market its generic version of Roche's Demadex, torsemide
tablets and a generic version of MedImmune's Ethyol, amifostine
for injection 500 mg.
Latest
rankings from ORG IMS
Shailesh Gadre, Managing Director, ORG IMS, shares some highlights
of the recently released MAT December 2007 figures and explains
why the combined retail and hospital audit figures give a
better picture of the Indian pharma industry. Viveka Roychowdhury
reports
Zydus
and Nycomed expand scope of JV models
Zydus Nycomed, the 50:50 joint venture company set up by Zydus
Cadila and Nycomed, will now be an API manufacturing hub,
with Nycomed planning to transfer its current API production
from facilities at Linz (Austria) and Singen (Germany) to
Zydus Nycomed in India over a period of four years.
Paving
way for newer trends
A one-day conference on research methodology was organised
by Maharashtra University of Health Science (MUHS), Nashik.
CCMB
collaborates with Purdue University
Centre for Cellular and Molecular Biology (CCMB) in Hyderabad,
India, was joined by researchers from Purdue University USA
for a two day symposium on "Bionanotechnology and pharmaceuticals—a
glimpse into the future", which was held on March 13
and 14.
'We
are leading from the front'
The 4th International Conference on Clinical Research recently
took place in Mumbai and undertook a volley of vital topics.
Arshiya Khan and Aashruti Kak report
Events
Brief
|
